Atea Pharmaceuticals, Inc. Stock Analysis & AI Score
Atea Pharmaceuticals, Inc. (AVIR) has an ST Score of 47.9 (C+), driven by its Financial Strength (A-) and held back by its Profitability (D). Analysts rate it Hold with a $7.00 price target (+35.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Atea Pharmaceuticals, Inc. (AVIR) has an ST Score of 47.9 (C+), driven by its Financial Strength (A-) and held back by its Profitability (D). Analysts rate it Hold with a $7.00 price target (+35.4% upside).
- Strongest
- Financial StrengthA-
- Weakest
- ProfitabilityD
All factor grades
- Financial StrengthA-
- MomentumA-
- ForecastB-
- ValuationC+
- GrowthC-
- ProfitabilityD
- Piotroski2/9
Contact
AVIR stock: frequently asked questions
What is AVIR's ST Score?
Atea Pharmaceuticals, Inc. (AVIR) has an ST Score of 47.9 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is AVIR a buy, hold, or sell?
Analysts rate AVIR a Hold, with a price target of $7.00 (+35.4% vs the current price). Our ST Score grades it C+ (47.9/100). The ST Score is a data-driven signal, not a recommendation.
What are AVIR's factor grades?
Valuation C+, Profitability D, Financial Strength A-, Momentum A-, Growth C-, Forecast B-.
What is AVIR's valuation grade?
Atea Pharmaceuticals, Inc. (AVIR) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is AVIR's growth grade?
Atea Pharmaceuticals, Inc. (AVIR) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is AVIR's profitability grade?
Atea Pharmaceuticals, Inc. (AVIR) earns a profitability grade of D, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is AVIR's financial strength grade?
Atea Pharmaceuticals, Inc. (AVIR) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for AVIR?
The average analyst price target for Atea Pharmaceuticals, Inc. (AVIR) is $7.00 from 4 analysts, which is +35.4% versus the recent price of $5.17.
What is AVIR's Piotroski score?
Atea Pharmaceuticals, Inc. (AVIR) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.